Stock A226950 OLIX PHARMACEUTICALS, INC
Add to a list
To use this feature you must be a member
Log inSign up

Financials OliX Pharmaceuticals, Inc

Equities

A226950

KR7226950004

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
15,670 KRW +1.10% Intraday chart for OliX Pharmaceuticals, Inc +2.82% +7.48%
Mar. 22 OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors CI
Mar. 20 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 14.7 billion in funding from a group of investors CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 444,868 276,877 681,166 561,830 278,859 233,568
Enterprise Value (EV) 1 397,811 241,559 627,582 560,684 260,984 247,001
P/E ratio -51.2 x -19.2 x -34.1 x -18.9 x -14.3 x -11 x
Yield - - - - - -
Capitalization / Revenue 1,473 x 245 x 275 x 153 x 29.9 x 13.7 x
EV / Revenue 1,317 x 214 x 254 x 153 x 28 x 14.5 x
EV / EBITDA -51.5 x -16.8 x -41.6 x -23.6 x -12.9 x -15.9 x
EV / FCF -59.7 x -37.1 x -85.3 x -64.8 x -13.3 x -6.93 x
FCF Yield -1.68% -2.7% -1.17% -1.54% -7.52% -14.4%
Price to Book 8.1 x 6.62 x 15 x 30.3 x 4.33 x 4.73 x
Nbr of stocks (in thousands) 13,008 13,060 13,542 13,703 13,703 16,020
Reference price 2 34,200 21,200 50,300 41,000 20,350 14,580
Announcement Date 3/29/19 3/12/20 3/15/21 3/15/22 3/15/23 3/14/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 302 1,130 2,474 3,674 9,320 17,064
EBITDA 1 -7,726 -14,341 -15,101 -23,794 -20,301 -15,543
EBIT 1 -8,234 -15,117 -16,241 -25,424 -22,376 -18,185
Operating Margin -2,726.47% -1,337.38% -656.41% -691.92% -240.07% -106.57%
Earnings before Tax (EBT) 1 -7,742 -14,244 -20,511 -31,099 -29,108 -18,170
Net income 1 -7,742 -14,353 -19,385 -29,715 -19,495 -19,102
Net margin -2,563.58% -1,269.79% -783.44% -808.7% -209.17% -111.94%
EPS 2 -667.5 -1,102 -1,474 -2,171 -1,423 -1,324
Free Cash Flow 1 -6,667 -6,512 -7,354 -8,649 -19,635 -35,664
FCF margin -2,207.69% -576.15% -297.23% -235.4% -210.67% -209%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/29/19 3/12/20 3/15/21 3/15/22 3/15/23 3/14/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - 13,433
Net Cash position 1 47,057 35,318 53,584 1,145 17,876 -
Leverage (Debt/EBITDA) - - - - - -0.8642 x
Free Cash Flow 1 -6,667 -6,512 -7,354 -8,649 -19,635 -35,664
ROE (net income / shareholders' equity) -21% -29.7% -44.5% -93.5% -65.7% -32.8%
ROA (Net income/ Total Assets) -13.3% -18.7% -16.4% -19.2% -12.8% -9.65%
Assets 1 58,128 76,598 118,193 154,513 152,874 197,875
Book Value Per Share 2 4,223 3,200 3,344 1,352 4,700 3,084
Cash Flow per Share 2 216.0 379.0 837.0 2,506 360.0 748.0
Capex 1 500 1,007 786 1,290 2,233 8,826
Capex / Sales 165.69% 89.08% 31.79% 35.11% 23.96% 51.72%
Announcement Date 3/29/19 3/12/20 3/15/21 3/15/22 3/15/23 3/14/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
OLIX PHARMACEUTICALS, INC Stock OliX Pharmaceuticals, Inc
+7.48% 187M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.65% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+6.75% 97.47B
ARGENX SE Stock argenx SE
+5.71% 22.25B
BIONTECH SE Stock BioNTech SE
-12.60% 21.68B
GENMAB A/S Stock Genmab A/S
-9.70% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.17% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.12% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.47% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A226950 Stock
  4. Financials OliX Pharmaceuticals, Inc